Intravenous keratinocyte growth factor protects against experimental pulmonary injury

Jane Guo, S. Yi Eunhee, Andrew M. Havill, Ildiko Sarosi, Lane Whitcomb, Songmei Yin, Scot C. Middleton, Pierre Piguet, Thomas R. Ulich

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Keratinocyte growth factor (KGF) administered by intratracheal instillation is well documented to stimulate the proliferation of alveolar and bronchial cells. In the present study, intravenous KGF was also shown to stimulate the proliferation of alveolar and bronchial cells in mice and rats, although to a lesser degree than intratracheal KGF. Despite the decreased potency of intravenous KGF on pulmonary cell 5-bromo-2'-deoxyuridine incorporation compared with intratracheal KGF, intravenous KGF was very effective in preventing experimental bleomycin-induced pulmonary dysfunction, weight loss, and mortality in either mice or rats and experimental hyperoxia- induced mortality in mice. The effectiveness of intravenous administration of KGF in preventing lung injury suggests that the mechanisms of the protective effect of KGF may involve more than pulmonary cell proliferation and also suggests the potential use of systemic KGF for clinical trials in settings of pulmonary injury.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume275
Issue number4 19-4
StatePublished - 1998
Externally publishedYes

Fingerprint

Fibroblast Growth Factor 7
Lung Injury
Alveolar Epithelial Cells
Lung
Hyperoxia
Mortality
Bleomycin
Bromodeoxyuridine
Intravenous Administration
Weight Loss
Cell Proliferation
Clinical Trials

Keywords

  • Bleomycin
  • Hyperoxia

ASJC Scopus subject areas

  • Cell Biology
  • Physiology
  • Physiology (medical)
  • Pulmonary and Respiratory Medicine

Cite this

Guo, J., Eunhee, S. Y., Havill, A. M., Sarosi, I., Whitcomb, L., Yin, S., ... Ulich, T. R. (1998). Intravenous keratinocyte growth factor protects against experimental pulmonary injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 275(4 19-4).

Intravenous keratinocyte growth factor protects against experimental pulmonary injury. / Guo, Jane; Eunhee, S. Yi; Havill, Andrew M.; Sarosi, Ildiko; Whitcomb, Lane; Yin, Songmei; Middleton, Scot C.; Piguet, Pierre; Ulich, Thomas R.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 275, No. 4 19-4, 1998.

Research output: Contribution to journalArticle

Guo, J, Eunhee, SY, Havill, AM, Sarosi, I, Whitcomb, L, Yin, S, Middleton, SC, Piguet, P & Ulich, TR 1998, 'Intravenous keratinocyte growth factor protects against experimental pulmonary injury', American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 275, no. 4 19-4.
Guo, Jane ; Eunhee, S. Yi ; Havill, Andrew M. ; Sarosi, Ildiko ; Whitcomb, Lane ; Yin, Songmei ; Middleton, Scot C. ; Piguet, Pierre ; Ulich, Thomas R. / Intravenous keratinocyte growth factor protects against experimental pulmonary injury. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 1998 ; Vol. 275, No. 4 19-4.
@article{8a27b1a8cf124eddaae2a718e6ae9778,
title = "Intravenous keratinocyte growth factor protects against experimental pulmonary injury",
abstract = "Keratinocyte growth factor (KGF) administered by intratracheal instillation is well documented to stimulate the proliferation of alveolar and bronchial cells. In the present study, intravenous KGF was also shown to stimulate the proliferation of alveolar and bronchial cells in mice and rats, although to a lesser degree than intratracheal KGF. Despite the decreased potency of intravenous KGF on pulmonary cell 5-bromo-2'-deoxyuridine incorporation compared with intratracheal KGF, intravenous KGF was very effective in preventing experimental bleomycin-induced pulmonary dysfunction, weight loss, and mortality in either mice or rats and experimental hyperoxia- induced mortality in mice. The effectiveness of intravenous administration of KGF in preventing lung injury suggests that the mechanisms of the protective effect of KGF may involve more than pulmonary cell proliferation and also suggests the potential use of systemic KGF for clinical trials in settings of pulmonary injury.",
keywords = "Bleomycin, Hyperoxia",
author = "Jane Guo and Eunhee, {S. Yi} and Havill, {Andrew M.} and Ildiko Sarosi and Lane Whitcomb and Songmei Yin and Middleton, {Scot C.} and Pierre Piguet and Ulich, {Thomas R.}",
year = "1998",
language = "English (US)",
volume = "275",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "4 19-4",

}

TY - JOUR

T1 - Intravenous keratinocyte growth factor protects against experimental pulmonary injury

AU - Guo, Jane

AU - Eunhee, S. Yi

AU - Havill, Andrew M.

AU - Sarosi, Ildiko

AU - Whitcomb, Lane

AU - Yin, Songmei

AU - Middleton, Scot C.

AU - Piguet, Pierre

AU - Ulich, Thomas R.

PY - 1998

Y1 - 1998

N2 - Keratinocyte growth factor (KGF) administered by intratracheal instillation is well documented to stimulate the proliferation of alveolar and bronchial cells. In the present study, intravenous KGF was also shown to stimulate the proliferation of alveolar and bronchial cells in mice and rats, although to a lesser degree than intratracheal KGF. Despite the decreased potency of intravenous KGF on pulmonary cell 5-bromo-2'-deoxyuridine incorporation compared with intratracheal KGF, intravenous KGF was very effective in preventing experimental bleomycin-induced pulmonary dysfunction, weight loss, and mortality in either mice or rats and experimental hyperoxia- induced mortality in mice. The effectiveness of intravenous administration of KGF in preventing lung injury suggests that the mechanisms of the protective effect of KGF may involve more than pulmonary cell proliferation and also suggests the potential use of systemic KGF for clinical trials in settings of pulmonary injury.

AB - Keratinocyte growth factor (KGF) administered by intratracheal instillation is well documented to stimulate the proliferation of alveolar and bronchial cells. In the present study, intravenous KGF was also shown to stimulate the proliferation of alveolar and bronchial cells in mice and rats, although to a lesser degree than intratracheal KGF. Despite the decreased potency of intravenous KGF on pulmonary cell 5-bromo-2'-deoxyuridine incorporation compared with intratracheal KGF, intravenous KGF was very effective in preventing experimental bleomycin-induced pulmonary dysfunction, weight loss, and mortality in either mice or rats and experimental hyperoxia- induced mortality in mice. The effectiveness of intravenous administration of KGF in preventing lung injury suggests that the mechanisms of the protective effect of KGF may involve more than pulmonary cell proliferation and also suggests the potential use of systemic KGF for clinical trials in settings of pulmonary injury.

KW - Bleomycin

KW - Hyperoxia

UR - http://www.scopus.com/inward/record.url?scp=0344753261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344753261&partnerID=8YFLogxK

M3 - Article

C2 - 9755113

AN - SCOPUS:0344753261

VL - 275

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 4 19-4

ER -